Journal
JOURNAL OF THE ENDOCRINE SOCIETY
Volume 3, Issue 5, Pages 965-972Publisher
ENDOCRINE SOC
DOI: 10.1210/js.2019-00036
Keywords
precocious puberty; treatment; GnRH analogs
Categories
Ask authors/readers for more resources
Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious puberty (CPP) worldwide and have an enviable track record of safety and efficacy. Recent years have witnessed much growth in the availability of longer-acting and sustained-release forms of GnRHas. Although all available agents appear promising, limited long-term follow-up and/or comparative data are available. In this review, important issues pertaining to the treatment of children with CPP are discussed. In addition to an assessment of the newer extended-release GnRHa formulations, a delineation of factors essential in determining which children should be treated is offered. Outstanding uncertainties in clinical management are highlighted and areas in need of future research identified. Literature searches for this review were performed in PubMed and OVID, with a focus on English-language publications using the terms central precocious puberty and treatment. Copyright (C) 2019 Endocrine Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available